All Posts
Evidence-based clinical practice guidelines for functional dyspepsia.
24 Jan, 2022 | 08:19h | UTCRelated:
Dyspepsia: A stepwise approach to evaluation and management.
UEG Consensus on Functional Dyspepsia.
AHA Statement: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease.
24 Jan, 2022 | 08:21h | UTCNews Release: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease – American Heart Association
The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly.
24 Jan, 2022 | 08:24h | UTCRelated:
ACP Guideline: Diagnosis and management of acute left-sided colonic diverticulitis.
Review: Changing paradigms in the management of acute uncomplicated diverticulitis.
Review: Elective surgical management of diverticulitis
State of the Art Review | Management of colonic diverticulitis
Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis
Systematic review: Management of colonic diverticulitis
WSES Guidelines for the Management of Acute Colonic Diverticulitis
ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.
24 Jan, 2022 | 08:18h | UTCEfficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)
News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases
Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay
RCT: Lactic acid gel vs. metronidazole for recurrent bacterial vaginosis in women aged 16 years and over.
24 Jan, 2022 | 08:13h | UTC
Review: Artificial intelligence in health and medicine.
24 Jan, 2022 | 08:16h | UTCAI in health and medicine – Nature Medicine (if the link is paywalled, try this one)
Related: High-Performance Medicine: The Convergence of Human and Artificial Intelligence
Commentary on Twitter (thread – click for more)
🆕 Our review of #AI for medicine, just published @NatureMedicine https://t.co/OAoAGmErns@pranavrajpurkar, Emma Chen, Oishi Banerjee pic.twitter.com/oufp3nnOob
— Eric Topol (@EricTopol) January 20, 2022
Perspective: Preventing digital overdiagnosis.
24 Jan, 2022 | 08:14h | UTCPreventing Digital Overdiagnosis – JAMA (free for a limited period)
Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)
Review: Health literacy interventions for secondary prevention of coronary artery disease.
24 Jan, 2022 | 08:12h | UTC
Review: Cardiovascular computed tomography imaging for coronary artery disease risk: plaque, flow and fat.
24 Jan, 2022 | 08:09h | UTC
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
Retrospective cohort study: Occurrence and predictors of pericardial effusion requiring invasive treatment following heart valve surgery.
24 Jan, 2022 | 08:10h | UTC
M-A: Impact of enhanced recovery protocols after pancreatoduodenectomy.
24 Jan, 2022 | 08:00h | UTCImpact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis – British Journal of Surgery (link to abstract – $ for full-text)
Related:
See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (some guidelines are free)
Commentary on Twitter
Do you apply @ErasSociety protocols 🤸♀️after pancreatoduodenectomy ?!
🌐 Meta analysis on > 3000 cases
⬇️ ERAS decreases overall morbidity, DGE, hospital stay, readmission rate
🏥 ERAS should be implemented, but in ALL patients?! https://t.co/fSmPYdof57 pic.twitter.com/L02q7bkLWU
— Giovanni Marchegiani (@Gio_Marchegiani) January 22, 2022
RCT: The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing esophageal cancer did not improve outcomes.
24 Jan, 2022 | 08:04h | UTCTrastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial in 203 pts with HER2+ oesophageal cancer, adding trastuzumab to neoadjuvant CRT did not significantly improve mDFS (19.6 vs 14.2 months; HR 0.99; P = 0.97). The incidence of grade 3 and 4 TRAEs was 43% & 21% vs 54% & 22%: https://t.co/wx0NmVMyCR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) January 21, 2022
KDOQI US commentary on the 2021 KDIGO Guideline for the management of blood pressure in chronic kidney disease.
24 Jan, 2022 | 07:56h | UTCRelated:
Commentary on Twitter
The @nkf KDOQI work group agreed with most of the @goKDIGO BP recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD ca. 2022 #Nephpearls
👉🏼 https://t.co/X40N0pacY6 https://t.co/HEHlSD06yO pic.twitter.com/Rpil8m0QOn
— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) January 21, 2022
Review: Histiocytic disorders.
24 Jan, 2022 | 08:02h | UTCHistiocytic disorders – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Histiocytic disorders (if the link is paywalled, try this one)
Commentary on Twitter
Haemophagocytic lympho #histiocytosis is a syndrome of extreme #immune activation; common manifestations include involvement of the central nervous system, hepatitis or acute liver failure.https://t.co/heXWqru8wW pic.twitter.com/1A0SFIhkwR
— Nature Reviews Disease Primers (@DiseasePrimers) January 21, 2022
Clinical review of subcutaneous Semaglutide for obesity.
24 Jan, 2022 | 07:54h | UTC
A faster way to find good medical treatments is gaining ground – “A type of clinical trial that tests many therapies at once is being used for COVID and Alzheimer’s”.
24 Jan, 2022 | 07:50h | UTCA Faster Way to Find Good Medical Treatments Is Gaining Ground – Scientific American
Opinion: COVID-19 will continue but the end of the pandemic is near.
21 Jan, 2022 | 10:16h | UTCCOVID-19 will continue but the end of the pandemic is near – The Lancet
Commentary on Twitter
.@IHME_UW's Chris Murray predicting the end of the pandemic is nigh
"More than 50% of the world will have been infected with omicron …[by] the end of March, 2022"
"After the omicron wave, COVID-19 will return but the pandemic will not."https://t.co/9NSw8lZuUe @TheLancet— Eric Topol (@EricTopol) January 20, 2022
Practical Guide: Management of bladder pain syndrome.
24 Jan, 2022 | 07:52h | UTCManagement of Bladder Pain Syndrome (BPS): A Practical Guide – Advances in Urology
Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials.
24 Jan, 2022 | 07:49h | UTC
Commentary from the author on Twitter (thread – click for more)
Our new paper is out now in @JAMANetworkOpen !
When a randomized trial designs a « Physicians’ choice » or « Investigators’ choice » control arm, you might think :
« Great, the control arm is standard of care ! »
➡️ you may be surprised 🧵👇🏻https://t.co/uho2pvXcG5— Timothée Olivier, MD (@Timothee_MD) January 21, 2022
RCT: Immunogenicity and reactogenicity of different vaccine boosters after a first J&J vaccine.
21 Jan, 2022 | 10:12h | UTC
Commentary on Twitter
Trial examined effects of boosting with one of the three approved #COVI19 vaccines — AD26.COV2.S, mRNA-1273, or BNT162b2 — 3 mos after the primary vaccination. All increased neutralizing-antibody levels & T-cell responses; mRNA vaccines were higher. https://t.co/qkpQFvNliJ pic.twitter.com/MUfa1OEsLP
— NEJM (@NEJM) January 19, 2022
Opinion: Now that science has defanged Covid, it’s time to get on with our lives.
21 Jan, 2022 | 10:14h | UTCNow that science has defanged Covid, it’s time to get on with our lives – The Guardian
See also: A National Strategy for the “New Normal” of Life With COVID – JAMA
Perspective: Nervous system consequences of COVID-19.
21 Jan, 2022 | 10:10h | UTCNervous system consequences of COVID-19 – Science
Related:
Review: Counting the neurological cost of COVID-19.
Neurological Effects of COVID-19 in Children.
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
Short review: Neurological complications of COVID-19.
2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.
M-A: Encephalitis as Neurological Complication of COVID‐19.
Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditionsEight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).
Commentary on Twitter
A new #SciencePerspective discusses the neurological symptoms that accompany #COVID19 and the possible mechanisms that cause them. Read more: https://t.co/WKZpnWlbNc pic.twitter.com/U4ohecaVQd
— Science Magazine (@ScienceMagazine) January 20, 2022
Review: Postdischarge Evaluation for Individuals Hospitalized with COVID-19.
21 Jan, 2022 | 10:08h | UTCPostdischarge Evaluation for Individuals Hospitalized with COVID-19 – Southern Medical Journal
Europe considers new COVID-19 strategy: Accepting the virus.
21 Jan, 2022 | 10:13h | UTCEurope considers new COVID-19 strategy: Accepting the virus – Associated Press